Dark

PRTA
Prothena Corporation plc
stock NASDAQ

At Close

Aug 4, 2026 3:59:57 PM EDT

8.48USD+2.106%(+0.17)329,912

7.12Bid 9.71Ask 2.59Spread

Pre-market

Jul 31, 2026 8:51:30 AM EDT

8.81USD+8.498%(+0.69)0

After-hours

Aug 4, 2026 4:00:30 PM EDT

8.49USD+0.059%(+0.01)88,521

OverviewOptionsHistoricalExchangesShortsNews

Jan 13, 2022

11:47AM EST The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact Benzinga

Jan 12, 2022

04:00PM EST CORRECTION: Proterra Ticker Is 'PTRA' Benzinga

10:30AM EST Mid-Morning Market Update: Markets Open Higher; US Inflation Rate Rises To 7% In December Benzinga

Nov 29, 2021

04:05PM EST Prothena Corporation plc(NASDAQ:PRTA), a late-stage clinical biotechnologycompany with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit on Monday December 6, 2021 at 1:20 PM ET. GlobeNewswire Inc

Nov 19, 2021

12:00PM EST Analyst Ratings For Prothena Corp Benzinga

10:09AM EST Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021 Benzinga

07:13AM EST JMP Securities Initiates Coverage On Prothena Corp with Market Outperform Rating, Announces Price Target of $77 Benzinga

Nov 5, 2021

12:06PM EDT Prothena Corp Earnings Perspective: Return On Capital Employed Benzinga

09:31AM EDT Prothena Corp Q3 EPS $2.13 Misses $2.28 Estimate, Sales $139.17M Miss $140.05M Estimate Benzinga

09:31AM EDT Prothena Corp: Q3 Earnings Insights Benzinga

Nov 4, 2021

05:00AM EDT Earnings Scheduled For November 4, 2021 Benzinga

Oct 12, 2021

07:21AM EDT CORRECTION: Protara Ticker Is 'TARA' Benzinga

07:01AM EDT Protara Therapeutics Announces FDA Clearance Of Investigational New Drug Application For TARA-002 For Treatment Of Non-Muscle Invasive Bladder Cancer Benzinga

Oct 1, 2021

04:30PM EDT Prothena Announces Inducement Grants Under Nasdaq Listing Rule GlobeNewswire Inc

04:09PM EDT Prothena Says CFO Tran Nguyen Has Been Appointed To Additional, Newly Created Role Of Chief Strategy Officer Benzinga

04:05PM EDT Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today announced that Chief Financial Officer Tran B. Nguyen has been appointed to the additional and newly created role of Chief Strategy Officer. Brandon Smith will take over as Chief Operating Officer. GlobeNewswire Inc

Sep 30, 2021

12:08PM EDT Expert Ratings For Prothena Corp Benzinga

07:09AM EDT RBC Capital Maintains Outperform on Prothena Corp, Raises Price Target to $82 Benzinga

Sep 28, 2021

08:30AM EDT Capital Metro To Acquire 26 Proterra ZX5 Max Electric Transit Buses; Terms Not Disclosed Benzinga

Sep 27, 2021

01:00PM EDT Expert Ratings For Prothena Corp Benzinga

07:09AM EDT Oppenheimer Maintains Outperform on Prothena Corp, Raises Price Target to $100 Benzinga

Sep 20, 2021

12:16PM EDT What 8 Analyst Ratings Have To Say About Prothena Corp Benzinga

11:49AM EDT Fox Advisors Initiates Coverage On Prothena Corp with Overweight Rating, Announces Price Target of $14 Benzinga

Sep 17, 2021

12:08PM EDT Expert Ratings For Prothena Corp Benzinga

07:54AM EDT Cantor Fitzgerald Maintains Overweight on Prothena Corp, Raises Price Target to $103 Benzinga

Sep 14, 2021

12:38PM EDT Expert Ratings For Prothena Corp Benzinga

07:34AM EDT Oppenheimer Maintains Outperform on Prothena Corp, Raises Price Target to $90 Benzinga

Sep 3, 2021

04:05PM EDT Prothena Announces Inducement Grant Under Nasdaq Listing Rule GlobeNewswire Inc

07:31AM EDT The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself Benzinga

Sep 2, 2021

11:32AM EDT Return on Capital Employed Insights for Prothena Corp Benzinga

Sep 1, 2021

04:05PM EDT Prothena Corporation plc(NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in the following September investor conferences: GlobeNewswire Inc

07:32AM EDT The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering Benzinga

Aug 31, 2021

08:15AM EDT The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical Benzinga

Aug 27, 2021

07:35AM EDT The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration Benzinga

Aug 9, 2021

12:24PM EDT What 9 Analyst Ratings Have To Say About Prothena Corp Benzinga

08:04AM EDT 10 Biggest Price Target Changes For Monday Benzinga

06:54AM EDT Oppenheimer Maintains Outperform on Prothena Corp, Raises Price Target to $82 Benzinga

Aug 5, 2021

04:34PM EDT Recap: Prothena Corp Q2 Earnings Benzinga

04:33PM EDT Prothena Corp Q2 EPS $0.58 Beats $0.55 Estimate, Sales $60.07M Beat $58.77M Estimate Benzinga

04:08AM EDT Earnings Scheduled For August 5, 2021 Benzinga

Jul 26, 2021

09:02AM EDT Prothena Highlights Presentation Of New Data From Alzheimer's Portfolio At Alzheimer's Association International Conference 2021 Benzinga

09:00AM EDT Prothena Presents New Data from Robust GlobeNewswire Inc

Jul 20, 2021

04:10PM EDT Prothena To Present Data From Two Of Its Alzheimer's Disease Programs At Alzheimer's Association International Conference 2021 Jul. 26 Benzinga

04:05PM EDT Prothena to Present Data from Two of its GlobeNewswire Inc

Jul 19, 2021

11:52AM EDT Where Prothena Corp Stands With Analysts Benzinga

08:16AM EDT RBC Capital Maintains Outperform on Prothena Corp, Raises Price Target to $59 Benzinga

Jul 13, 2021

02:00PM EDT Where Prothena Corp Stands With Analysts Benzinga

09:16AM EDT Citigroup Maintains Buy on Prothena Corp, Raises Price Target to $72 Benzinga

08:15AM EDT 10 Biggest Price Target Changes For Tuesday Benzinga

07:13AM EDT Oppenheimer Maintains Outperform on Prothena Corp, Raises Price Target to $76 Benzinga

06:11AM EDT HC Wainwright & Co. Maintains Buy on Prothena Corp, Raises Price Target to $75 Benzinga

Jul 12, 2021

02:31PM EDT Mid-Afternoon Market Update: Dow Surges Over 100 Points; State Auto Financial Shares Jump Benzinga

12:24PM EDT Mid-Day Market Update: Crude Oil Down 1%; Celldex Therapeutics Shares Spike Higher Benzinga

10:27AM EDT Mid-Morning Market Update: Markets Mostly Higher; Novo Nordisk To Acquire Prothena's ATTR Amyloidosis Program Benzinga

08:30AM EDT Novo Nordisk To Buy Prothena's ATTR Amyloidosis Program For Up To $1.2B Benzinga

07:51AM EDT Prothena Corporation plc (PRTA), a late-stage clinical company, announced Monday a definitive purchase agreement, under which it sold clinical stage antibody PRX004 and broader ATTR amyloidosis programme to Novo Nordisk A/S (NVO). RTTNews

07:27AM EDT Novo Nordisk Buys Prothena's Clinical Stage Antibody PRX004 And Broader ATTR Amyloidosis Programme RTTNews

07:05AM EDT Prothena And Novo Nordisk Announce Definitive Purchase Agreement Under Which Novo Nordisk Acquired Prothena's PRX004 And Broader ATTR Amyloidosis Program; Prothena Eligible To Receive $1.2B In Sales Milestones Including $100M In Upfront/Near-Term Payments Benzinga

07:02AM EDT -- Prothena is eligible to receive development and sales milestone payments totalling up to 1.2 billion US dollars, including 100 million dollars in upfront and near-term clinical milestone payments -- Novo Nordisk will develop the phase 2 ready antibody PRX004 for the rare heart disease ATTR cardiomyopathy GlobeNewswire Inc

Jul 9, 2021

11:07AM EDT Shares of Prothena Corp. plc (PRTA) are gaining over 12% on Friday morning despite no stock-related news statement from the company. RTTNews

Jun 24, 2021

08:59AM EDT Bristol Myers Squibb exercised its option under the global neuroscience research and development collaboration to enter into an exclusive U.S. license for PRX005. Bristol Myers will pay Prothena $80 million, Prothena Corporation plc (PRTA) said in a statement. RTTNews

08:43AM EDT Prothena To Receive $80 Mln From Bristol Myers Squibb For Exclusive US License To PRX005 RTTNews

08:32AM EDT Prothena Announces Bristol Myers Squibb Opt-In Of Anti-Tau PRX005 As First Program From Global Neuroscience Research And Development Collaboration Benzinga

08:30AM EDT -- Prothena to receive $80 million from Bristol Myers Squibb for exclusive US license to PRX005; Next option for worldwide rights following completion of Phase 1 -- PRX005 is an investigational best-in-class anti-tau antibody targeting the microtubule binding region of tau for the treatment of Alzheimers disease -- Phase 1 study has initiated GlobeNewswire Inc

Jun 22, 2021

01:50PM EDT CORRECTION: Proterra Ticker Is 'PTRA' Benzinga

Jun 18, 2021

12:47PM EDT Benzinga's Top Ratings Upgrades, Downgrades For June 18, 2021 Benzinga

10:22AM EDT Return On Capital Employed Overview: Prothena Corp Benzinga

07:33AM EDT B of A Securities Upgrades Prothena Corp to Neutral, Announces $49 Price Target Benzinga

Jun 11, 2021

07:48AM EDT 10 Biggest Price Target Changes For Friday Benzinga

07:00AM EDT RBC Capital Maintains Outperform on Prothena Corp, Raises Price Target to $50 Benzinga

Jun 10, 2021

02:18PM EDT Prothena Corporation plc(NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in a fireside chat at the JMP Securities Life Sciences Conference on Wednesday, June 16 at 3:00 PM ET GlobeNewswire Inc

08:12AM EDT 10 Biggest Price Target Changes For Thursday Benzinga

06:10AM EDT HC Wainwright & Co. Maintains Buy on Prothena Corp, Raises Price Target to $58 Benzinga

Jun 4, 2021

10:50AM EDT Return On Capital Employed Overview: Prothena Corp Benzinga

May 26, 2021

10:09AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 26, 2021 Benzinga

07:32AM EDT Citigroup Initiates Coverage On Prothena Corp with Buy Rating, Announces Price Target of $39 Benzinga

May 20, 2021

04:05PM EDT Prothena Corporation plc(NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced today the appointment ofSanjiv K. Patel, MBBS, MA, MBA,to its Board of Directors. GlobeNewswire Inc

May 11, 2021

04:33PM EDT Prothena Continues To Expect The FY21 Net Cash Used In Operating And Investing Activities To Be $51M-$74M, Which Includes Receiving The $60M Milestone Earned In TheQ2 From Roche Benzinga

04:29PM EDT Prothena Corp Q1 EPS $(0.91) Down From $(0.59) YoY, Sales $160.00K Up From $141.00K YoY Benzinga

04:05PM EDT Prothena Reports First Quarter 2021 Financial Results and Provides GlobeNewswire Inc

12:47PM EDT Earnings Scheduled For May 11, 2021 Benzinga

07:54AM EDT The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings Benzinga

06:57AM EDT Prothena Receives $60M Milestone Payment After Parkinson's Candidate Moves Forward In Mid-Stage Study With Dosing Benzinga

04:14AM EDT Earnings Scheduled For May 11, 2021 Benzinga

May 10, 2021

04:18PM EDT Prothena Announced The Achievement Of $60M Milestone From Roche For The First Patient Dosed In Its Phase 2b Study Of Prasinezumab In Early Parkinson's Disease Benzinga

04:05PM EDT Prothena Announces Achievement of $60 Million Milestone From Roche GlobeNewswire Inc

May 7, 2021

04:05PM EDT Prothena Announces Inducement Grant Under Nasdaq Listing Rule GlobeNewswire Inc

May 4, 2021

04:05PM EDT Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, announced today that it will report its first quarter 2021 financial results on Tuesday, May 11, 2021 after the close of the U.S. financial markets. GlobeNewswire Inc

Apr 18, 2021

03:47PM EDT Prothena Presented Phase 1 Study Results Of PRX004 In Oral Presentation At AAN 2021; Said Slowing of Neuropathy Progression for All 7 Evaluable Patients, Evidenced by a +1.29 Point Mean Change in Nis, Was More Favorable Than Expected Progression of +9.2 Points Benzinga

03:05PM EDT Prothena Presents Phase 1 Study Results of PRX004 in Oral GlobeNewswire Inc

Apr 15, 2021

04:10PM EDT Prothena Corporation To Present PRX004 Phase 1 Study Results At AAN 2021 Apr. 18 Benzinga

04:05PM EDT Prothena Announces PRX004 Phase 1 Study Results Selected for GlobeNewswire Inc

Apr 7, 2021

04:05PM EDT Prothena Announces Inducement Grants Under Nasdaq Listing Rule GlobeNewswire Inc

Apr 5, 2021

04:05PM EDT Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical Officer Benzinga

04:05PM EDT Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief GlobeNewswire Inc

Mar 28, 2021

08:15AM EDT The Past Week's Notable Insider Buys: Babcock & Wilcox, Designer Brands And More Benzinga

Mar 26, 2021

07:28AM EDT The Daily Biotech Pulse: FDA Nod For Astellas, Seagen, Gilead Get Positive Regulatory Tidings From Europe, 3 IPOs Benzinga

Mar 25, 2021

11:19AM EDT Prothena Form 4 Filing Shows Purchase From EcoR1 Capital Of 875K Shares At Average Share Price $20.75/Share Benzinga

Mar 24, 2021

08:59AM EDT The Daily Biotech Pulse: Dynavax-Clover Start Phase 2/3 Vaccine Study. BrainStorm Reports Positive MS Readout, NeoGenomics Goes Shopping Benzinga

08:13AM EDT Prothena Says Pricing Of Public Offering Of 3.5M Ordinary Shares At $20.75/Share Benzinga

08:00AM EDT Prothena Announces Pricing of Public Offering of 3,500,000 GlobeNewswire Inc

Mar 23, 2021

04:30PM EDT Prothena Announces Proposed Offering of Ordinary Shares; No Terms Disclosed Benzinga

04:29PM EDT Prothena Announces Proposed Offering of Ordinary Shares GlobeNewswire Inc

Mar 11, 2021

10:09AM EST Prothena To Hold Investor Webcast Thursday, Mar. 11, Starting At 4:30 p.m. EST (Webcast Link) Benzinga

08:19AM EST The Daily Biotech Pulse: Contrasting COVID-19 Treatment Readouts From Roche, Vir, Delay In Kadmon's FDA Review, Alzheimer's Data From Prothena Benzinga

Mar 8, 2021

04:05PM EST Prothena to Hold Investor Webcast to Review Three Oral GlobeNewswire Inc

08:34AM EST Benzinga Pro's Top 5 Stocks To Watch For Monday, Mar. 8, 2021: USO, GME, LGHL, PRTA, BLDP Benzinga

Mar 6, 2021

10:58AM EST The Week Ahead In Biotech (March 7-13): Conference Presentations And More Earnings Benzinga

Feb 24, 2021

04:05PM EST -- Robust preclinical data support the benefit of PRX005, a novel anti-tau antibody, for the potential treatment Alzheimers disease -- New pre-specified exploratory subgroup analyses and new digital biomarker data from Part 1 of the Phase 2 PASADENA study of prasinezumab in patients with early Parkinsons disease will be featured in two separate presentations GlobeNewswire Inc

Feb 20, 2021

02:17PM EST The Past Week's Notable Insider Buys: More Biotech IPOs, Bumble, Fiserv And More Benzinga

Feb 19, 2021

07:25AM EST The Daily Biotech Pulse: Novavax Vaccine Supply Deal, Orphan Drug Designation For Travere, COVID-19 Boost For Quidel, Opko Benzinga

Feb 18, 2021

08:14AM EST The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout Benzinga

05:54AM EST Prothena 10%+ Owner Ecor1 Capital, Llc Reported Purchase of 635,840 Shares @ Avg Price of $21.49/Share in Form 4 Filing on Wednesday Benzinga

Feb 17, 2021

07:27AM EST The Daily Biotech Pulse: Novartis Funding For Gene Therapy Research, Priority Review For Amgen Cancer Drug, Pfizer-BioNTech Vaccine Supply Deal Benzinga

Feb 12, 2021

10:06AM EST Benzinga's Top Ratings Upgrades, Downgrades For February 12, 2021 Benzinga

06:03AM EST Jefferies Upgrades Prothena Corp to Buy, Raises Price Target to $30 Benzinga

Feb 11, 2021

11:21AM EST Stocks That Hit 52-Week Highs On Thursday Benzinga

08:00AM EST -- Net cash used in operating and investing activities was $19.1 million in the fourth quarter and $80.6 million for the full year 2020; quarter-end cash and restricted cash position of $298.1 million provides funding to advance the R&D pipeline GlobeNewswire Inc

03:51AM EST Earnings Scheduled For February 11, 2021 Benzinga

Feb 10, 2021

07:34AM EST The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs Benzinga

Feb 9, 2021

08:10AM EST The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement Benzinga

Feb 5, 2021

04:05PM EST Prothena Announces Inducement Grant Under Nasdaq Listing Rule GlobeNewswire Inc

Feb 4, 2021

04:05PM EST Prothena to Report Fourth Quarter and Full Year 2020 Financial GlobeNewswire Inc

08:16AM EST HC Wainwright & Co. Maintains Buy on Prothena Corp, Raises Price Target to $33 Benzinga

Feb 2, 2021

11:42AM EST Oppenheimer Maintains Outperform on Prothena Corp, Raises Price Target to $35 Benzinga

10:21AM EST BTIG Upgrades Prothena Corp to Buy, Announces $29 Price Target Benzinga

Feb 1, 2021

04:22PM EST Prothena Shares To Resume Trade At 4:45 p.m. EST Benzinga

04:16PM EST Prothena Reports Confirmatory Phase 3 AFFIRM-AL Study Of Birtamimab For AL Myloidosis: 'Significant survival benefit observed in VITAL study for birtamimab-treated patients with AL amyloidosis at high risk for early mortality' Benzinga

04:15PM EST Prothena Announces Confirmatory Phase 3 AFFIRM-AL Study of GlobeNewswire Inc

04:12PM EST Prothena Shares Halted News Pending Benzinga

Dec 9, 2020

08:22AM EST Prothena Shares To Resume Trade At 8:30 a.m. EST Benzinga

08:01AM EST Prothena Reports 9-Month Results From Phase 1 Long-Term Extension Study Of PRX004: 'Slowing of neuropathy progression for all 7 evaluable patients,' 'Improvement in neuropathy for 3 of these 7 evaluable patients' Benzinga

08:00AM EST Prothena Reports Positive 9 Month Results from Phase 1 Long-term GlobeNewswire Inc

Dec 7, 2020

10:10AM EST Benzinga's Top Upgrades, Downgrades For December 7, 2020 Benzinga

06:59AM EST HC Wainwright & Co. Initiates Coverage On Prothena Corp with Buy Rating, Announces Price Target of $22 Benzinga

Dec 4, 2020

04:05PM EST Prothena Announces Inducement Grant Under Nasdaq Listing Rule GlobeNewswire Inc

Nov 4, 2020

04:29PM EST Prothena Corp Q3 EPS $(0.77) Misses $(0.65) Estimate, Sales $157.00K Miss $170.00K Estimate Benzinga

04:06PM EST Prothena Reports Third Quarter 2020 Financial Results and Provides GlobeNewswire Inc

11:42AM EST Prothena Publishes Poster For Clinical Trials On Alzheimer's Disease Nov. 4-7, 'Novel Amyloid Beta Monoclonal Antibodies With Superior Binding Properties...' Benzinga

08:32AM EST Prothena Announces Presentations On Two Programs From Its Alzheimer's Disease Portfolio At CTAD 2020 Benzinga

08:30AM EST -- Next generation anti-Aantibodies being developed for subcutaneous administration to improve access for patientswith Alzheimers disease -- Multi-immunogen A-tau vaccine being developed for the prevention and treatment of Alzheimers disease GlobeNewswire Inc

04:41AM EST Earnings Scheduled For November 4, 2020 Benzinga

Oct 28, 2020

04:05PM EDT Prothena to Report Third Quarter 2020 Financial Results on November 4 GlobeNewswire Inc

Oct 21, 2020

08:04AM EDT The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings Benzinga

07:44AM EDT Cantor Fitzgerald Maintains Overweight on Prothena Corp, Raises Price Target to $24 Benzinga

Oct 20, 2020

06:08PM EDT Prothena Corporation plc (PRTA) announced plans to advance prasinezumab into a Phase 2b study, along with Roche (RHHBY), in patients with early Parkinson's disease, based on positive signals of efficacy consistent with disease modification in the PASADENA study. Prasinezumab is the first anti-alpha synuclein antibody to advance into late-stage development. RTTNews

05:50PM EDT 16 Stocks Moving In Tuesday's After-Hours Session Benzinga

04:26PM EDT Roche, Prothena Plan To Advance Prasinezumab Into Phase 2b Study For Parkinson's Disease RTTNews

04:12PM EDT Prothena Reports Plan, With Roche, To Advance Prasinezumab Into Phase 2b Study In Patients With Early Parkinson's Disease Benzinga

04:05PM EDT -- First anti-alpha-synuclein antibody to advance intoconfirmatory large study in patients with early Parkinsons disease; expected to initiate in 2021 -- Prothena to earn a $60 millionclinical milestoneupon first patient dosed GlobeNewswire Inc

Oct 2, 2020

04:05PM EDT Prothena Announces Inducement Grant Under Nasdaq Listing Rule GlobeNewswire Inc

Sep 15, 2020

08:34AM EDT Prothena To Hold Investor Webcast To Discuss Results From Phase 2 PASADENA Study Presented At The International Parkinson And Movement Disorder Society's MDS Virtual Congress Benzinga

08:30AM EDT Prothena to Hold Investor Webcast to Discuss Results from Phase 2 GlobeNewswire Inc

Sep 14, 2020

08:27AM EDT Benzinga Pro's Top 5 Stocks To Watch For Monday, Sept. 14, 2020: ORCL, NVDA, ADBE, BHC, PRTA Benzinga

Sep 11, 2020

08:40AM EDT Prothena Reports Results From Phase 2 PASADENA Study Of Prasinezumab Show 'Significantly reduced decline in motor function by 35% vs. placebo at one year' Benzinga

08:30AM EDT Prasinezumab Slows Progression on Measures of GlobeNewswire Inc

Sep 8, 2020

04:05PM EDT Prothena to Present at the 2020 Cantor Virtual Global Healthcare GlobeNewswire Inc

Sep 3, 2020

04:05PM EDT Prothena Announces Updated Timing of Presentation for Phase 2 GlobeNewswire Inc

Sep 2, 2020

04:05PM EDT Prothena Announces Inducement Grant Under Nasdaq Listing Rule GlobeNewswire Inc

Aug 6, 2020

04:49PM EDT Prothena Corp Q2 EPS $(0.66) Misses $(0.61) Estimate, Sales $200.00K Beat $150.00K Estimate Benzinga

Aug 5, 2020

04:05PM EDT -- Phase 2 PASADENA Part 1 study results selected as an oral Top Abstract GlobeNewswire Inc